Epigenetic modulation enhances immunotherapy for pancreatic ductal adenocarcinoma

Epigenetic modulation enhances immunotherapy for pancreatic ductal adenocarcinoma

Abstract Objectives Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with a poor prognosis. PDAC has poor response to immunotherapy because of its unique tumour microenvironment (TME). In an attempt to stimulate immunologically silent pancreatic cancer, we investigated the role of ep...

Full description

Bibliographic Details
Main Authors: Yan Li, Young K Hong, Xingtong Wang, Harshul Pandit, Qianqian Zheng, Youxi Yu, Xiaoju Shi, Yujia Chen, Min Tan, Zachary Pulliam, Neal Bhutiani, Andrew Lin, Jeremy Badach, Ping Zhang, Robert CG Martin
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Clinical & Translational Immunology
Subjects:
checkpoint inhibitors
epigenetic modulation
immunotherapy
pancreatic ductal adenocarcinoma (PDAC)
Online Access:https://doi.org/10.1002/cti2.1430

Internet

https://doi.org/10.1002/cti2.1430

Similar Items